Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Regen BioPharma (RGBPP) over the last 12 years, with Q4 2025 value amounting to $237076.0.

  • Regen BioPharma's Liabilities and Shareholders Equity rose 2385.38% to $237076.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $878027.0, marking a year-over-year increase of 3234.86%. This contributed to the annual value of $274628.0 for FY2025, which is 7048.74% up from last year.
  • As of Q4 2025, Regen BioPharma's Liabilities and Shareholders Equity stood at $237076.0, which was up 2385.38% from $274628.0 recorded in Q3 2025.
  • In the past 5 years, Regen BioPharma's Liabilities and Shareholders Equity registered a high of $1.4 million during Q2 2021, and its lowest value of $140770.0 during Q1 2024.
  • Over the past 5 years, Regen BioPharma's median Liabilities and Shareholders Equity value was $279912.0 (recorded in 2023), while the average stood at $429955.3.
  • Per our database at Business Quant, Regen BioPharma's Liabilities and Shareholders Equity surged by 140160.36% in 2021 and then crashed by 6538.17% in 2024.
  • Quarter analysis of 5 years shows Regen BioPharma's Liabilities and Shareholders Equity stood at $735241.0 in 2021, then tumbled by 43.68% to $414108.0 in 2022, then tumbled by 61.48% to $159528.0 in 2023, then increased by 19.99% to $191416.0 in 2024, then increased by 23.85% to $237076.0 in 2025.
  • Its Liabilities and Shareholders Equity was $237076.0 in Q4 2025, compared to $274628.0 in Q3 2025 and $196841.0 in Q2 2025.